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Abstract
Twelve patients with refractory acute leukemia (7 patients with acute myelocytic leukemia
and 5 patients with acute lymphocytic leukemia) were treated with a new anthracycline antibi-
otic, aclacinomycin-A (ACM). ACM was administrated by intravenous drip infusion at a dose
of 20 mg/day for 7 or 14 days and this was repeated after at least 7 days. Four of 12 patients
(33.3%) achieved a complete remission; 3 of 7 acute myelocytic leukemia (42.8%) and 1 of 5
acute lymphocytic leukemia (20.0%). The days required for achieving the complete remission
ranged from 23 to 78 days (median: 61) and the total doses of ACM used from 180 to 500 mg
(median: 310), and the durations of complete remission from 11 to 28+ weeks (median: 21+). The
untoward effects on digestive organs, such as nausea, vomiting and anorexia, and hematological
toxicities were frequently seen; however, they were controlled by supportive treatment. Alopecia
was not observed. Arrythmia was recognized in one patient at the initiation of ACM infusion with
complete remission without withdrawal of ACM. These results suggest that ACM is a potentially
effective anthracycline antibiotic in the clinical management of acute leukemia.
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